参考文献：1.Borst J, Busselaar J, Bosma DMT, Ossendorp F. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021 Aug;51(8):1911-1920.2.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radi...
Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosisPD-1PD-L1Immune checkpointIdiopathic pulmonary fibrosisMechanism of actionTreatmentLung cancerIdiopathic pulmonary fibrosis (IPF) is a globally prevalent, progressi...
Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021 Aug;51(8):1911-1920. 2.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-...
Consistent with this mechanism of action, PDLIM2 deficiency results in increased amounts of nuclear p65 and augmented production of proinflammatory cytokines 1Laboratory for Inflammatory Regulation, RIKEN Center for Integrative Medical Sciences (IMS), RIKEN Research Center for Allergy and Immunology (RCAI...
The mechanism of action of the PD-1/PD-L1 axis in IPF is not yet fully elucidated and further exploration is needed. We summarize the results of current PD-1/PD-L1 inhibitors in IPF studies below to explore the feasibility of targeting PD-1/PD-L1 for the treatment of IPF. ...
(AA@PN) co-loaded with APP and HAuNS were prepared by single emulsion method. The mechanism of action of AA@PN is shown in Fig.9a. To increase the tumor suppressive effect of AA@PN, AA@PN was co-administered with cytosine-phosphate-guanine (CpG) immune adjuvant (Fig.9b). The ...
Soon after that, scientists elucidated its signaling mechanism. In 2014, the US FDA granted accelerated approval to pembrolizumab (brand name: Keytruda, Merck’s PD-1 inhibitor), a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, for ...
2 Mechanism of action of anti-PD-1 and anti-PD-L1 antibodies. a In a PD-L1 negative tumour, tumour neoantigens presented on the surface of tumour cells or APCs are detected by T cells, which are then activated to destroy the tumour cell. b Tumour cell or APC expression of PD-L1 ...
In RCC the expression of PD-L1 on tumor cells was prognostic but not predictive in the pivotal study that led to the approval of the PD-1 inhibitor Nivolumab in RCC patients upon progression on previous therapy (Xu et al., 2015, Motzer et al., 2015). Advanced urothelial bladder cancer ...
What do we know about its mechanism of action? And how might a PD-1 or a PD-(L)1 inhibitor work in addition to, or maybe even synergistically with, BCG, so that we could justify combining the two? Bernie Eigl: I work with immunotherapies all the time, but truly, BCG is probably ...